Status:

COMPLETED

Heterosubtypic Immune Responses to Influenza in Older People

Lead Sponsor:

University Hospitals, Leicester

Collaborating Sponsors:

Centers for Disease Control and Prevention

Public Health England

Conditions:

Influenza

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Vaccination is the principal means of combating epidemic and pandemic influenza. As vaccines induce relatively strain-specific and short-lived antibody responses, annual immunisation with regularly up...

Detailed Description

STUDY OBJECTIVES: Immunological objectives * To evaluate heterosubtypic neutralising antibody to influenza viruses in older people * To evaluate heterosubtypic neutralising antibody responses to hum...

Eligibility Criteria

Inclusion

  • Subjects aged over 18 years of age, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol;
  • Subjects willing to be enrolled in the vaccine study if appropriate from prescreening blood test results
  • In good health as determined by:
  • medical history,
  • physical examination,
  • clinical judgment of the Investigator;
  • Able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for study visits

Exclusion

  • Receipt of another investigational agent within 4 weeks, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
  • Subjects who experienced any acute disease or infection requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) within the past 7 days before Visit 1 or any visit where trial vaccination is planned;
  • Subjects who experienced fever (within 3 days prior to Visit 1;
  • Subjects who are pregnant or breastfeeding;
  • Females of childbearing potential who refuse to use an acceptable method of birth control for the duration of the study.
  • Subjects with any serious disease, such as:
  • cancer,
  • autoimmune disease (including rheumatoid arthritis),
  • progressive chronic pulmonary disease (stable controlled respiratory disease including asthma is allowed),
  • acute or progressive hepatic disease,
  • acute or progressive renal disease;
  • Subjects for whom elective surgery is planned during the study period;
  • Subjects with bleeding diathesis;
  • Subjects with hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine;
  • Subjects with a history of any neurological symptoms or signs, or anaphylactic shock following administration of any vaccine;
  • Subjects with known or suspected impairment/alteration of immune function, for example, resulting from:
  • receipt of immunosuppressive therapy (any corticosteroid therapy or cancer chemotherapy),
  • receipt of immunostimulants,
  • receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
  • high risk for developing an immunocompromising disease;
  • Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination;
  • Subjects with a history of (or current) drug or alcohol abuse that in the investigator's opinion would interfere with safety of the subject or the evaluation of study objectives;
  • Subjects with any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.
  • \-

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2013

Estimated Enrollment :

292 Patients enrolled

Trial Details

Trial ID

NCT00798343

Start Date

January 1 2009

End Date

September 1 2013

Last Update

June 3 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals Leicester

Leicester, Leicestershire, United Kingdom, LE1 5WW